Adverts

Open Access Articles- Top Results for Carmustine

Carmustine

Template:Chembox UNII
Carmustine
Skeletal formula of carmustine
Ball-and-stick model of carmustine molecule
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Names

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

IUPAC name
1,3-Bis(2-chloroethyl)-1-nitrosourea[1]
Other names
N,N’-Bis(2-chloroethyl)-N-nitroso-urea[citation needed]
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Identifiers

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-


ATC code L01AD01
154-93-8 7pxY
ChEBI CHEBI:3423 7pxY
ChEMBL ChEMBL513 7pxY
ChemSpider 2480 7pxY
DrugBank DB00262 7pxY
EC number 205-838-2
Jmol-3D images Image
KEGG D00254 7pxN
MeSH Carmustine
PubChem Template:Chembox PubChem/format
RTECS number YS2625000
UN number 2811
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Properties

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

C5H9Cl2N3O2
Molar mass Lua error in Module:Math at line 495: attempt to index field 'ParserFunctions' (a nil value). g·mol−1
Appearance Orange crystals
Odor Odourless
Melting point Script error: No such module "convert".
log P 1.375
Acidity (pKa) 10.194
Basicity (pKb) 3.803
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Pharmacology

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-


Bioavailability 5–28%
  • Intravenous
  • Intralesional
Metabolism Hepatic
15–30 min
Protein binding 80%
Excretion
  • Renal
  • Respiratory
Legal status
  • (Prescription only)
  • US: D (Evidence of risk)
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Hazards

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-


GHS pictograms The skull-and-crossbones pictogram in the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) The health hazard pictogram in the Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
GHS signal word DANGER
H300, H350, H360
P301+310, P308+313
EU classification Very Toxic T+
R-phrases R45, R46, R60, R61, R28
S-phrases S22, S36/37/39, S45
20 mg kg−1 (oral, rat)
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Related compounds

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-


Related ureas
Dimethylurea
Related compounds
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 14pxN verify (what is10pxY/10pxN?)
Infobox references

Carmustine (bis-chloroethylnitrosourea, BCNU, BiCNU) is a mustard gas-related β-chloro-nitrosourea compound used as an alkylating agent in chemotherapy. As a dialkylating agent, BCNU is able to form interstrand crosslinks in DNA, which prevents DNA replication and DNA transcription.

It has the appearance of an orange-yellow solid.

Carmustine for injection was earlier marketed under the name BiCNU by Bristol-Myers Squibb[2] and now by Emcure Pharmaceuticals.[3] In India it is sold under various brand names including Consium .

Uses

It is used in the treatment of several types of brain cancer (including glioma, glioblastoma multiforme, medulloblastoma and astrocytoma), multiple myeloma and lymphoma (Hodgkin's and non-Hodgkin). BCNU is sometimes used in conjunction with alkyl guanine transferase (AGT) inhibitors, such as O6-benzylguanine. The AGT-inhibitors increase the efficacy of BCNU by inhibiting the direct reversal pathway of DNA repair, which will prevent formation of the interstrand crosslink between the N1 of guanine and the N3 of cytosine.

It is also used as part of a chemotherapeutic protocol in preparation for hematological stem cell transplantation, a type of bone marrow transplant, in order to reduce the white blood cell count in the recipient (patient). Use under this protocol, usually with Fludarabine and Melphalan, was coined by oncologists at the University of Texas MD Anderson Cancer Center.

Implants

In the treatment of brain tumours, the U.S. Food and Drug Administration (FDA) approved biodegradable discs infused with carmustine (Gliadel).[4] They are implanted under the skull during a surgery called a craniotomy.[5] The disc allows for controlled release of carmustine in the extracellular fluid of the brain, thus eliminating the need for the encapsulated drug to cross the blood-brain barrier.[6]

See also

References

External links